Skip to main content

Table 2 Comparisons of sVCAM-1, 120 min NEFA, AUCins and ΔI30/ΔG30 levels after 8-week treatment between liraglutide and metformin group

From: Liraglutide suppresses non-esterified free fatty acids and soluble vascular cell adhesion molecule-1 compared with metformin in patients with recent-onset type 2 diabetes

Variable

Liraglutide

Metformin

Difference

P-value

sVCAM-1 (ng/ml)

382 ± 131

503 ± 182

 

0.046

120 min NEFA (μmol/L)a

− 32 (− 96, − 5)

5 (− 35, 38)

− 20.5 (− 46.5, 31.5)

0.033

AUCins (mIU/L)a

738 (451, 1118)

594 (357, 1216)

39 (− 33, 227)

0.014

ΔI30/ΔG30a

6.01 (1.79, 28.46)

− 2.62 (− 14.85,8.76)

4.56 (− 4.82, 12.99)

0.065

  1. Data are expressed as mean ± standard deviation or median (interquartile rang)
  2. sVCAM-1 soluble vascular cell adhesion molecule-1, NEFA non-esterified fatty acids, AUCins insulin area under the curve
  3. ΔI30/ΔG30 = [(insulin at 30 min) − (insulin at 0 min)]/[(glucose at 30 min) − (glucose at 0 min)]
  4. aDifference between pre-treatment and post-treatment